Cargando…

Drug safety of frequently used drugs and substances for self-medication in COVID-19

During the COVID-19 pandemic, the behavior of self-medication has increased. The dissemination of misleading information regarding the efficacy of certain drugs or substances for the prevention and treatment of COVID-19 has been the major contributing factor for this phenomenon. Alongside with the i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baracaldo-Santamaría, Daniela, Pabón-Londoño, Santiago, Rojas-Rodriguez, Luis Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Self-Medication and Pharmacovigilance in the Era of Infodemic
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039440/ https://www.ncbi.nlm.nih.gov/pubmed/35493401 http://dx.doi.org/10.1177/20420986221094141

Ejemplares similares

Definition of self-medication: a scoping review
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Prescription for COVID-19 by non-medical professionals during the pandemic in Colombia: a cross-sectional study
por: Nino-Orrego, Maria Jose, et al.
Publicado: (2022)

Impact of risk communication on patient’s safety during the pandemic
por: Zuluaga-Arias, Heyde-Patricia, et al.
Publicado: (2023)

Enhancing self-medication practices in the era of infodemic: the role of pharmacovigilance
por: Calderon-Ospina, Carlos-Alberto
Publicado: (2023)

Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge
por: Rudolph, Annette, et al.
Publicado: (2022)

Self-medication and the ‘infodemic’ during mandatory preventive isolation due to the COVID-19 pandemic
por: Gaviria-Mendoza, Andrés, et al.
Publicado: (2022)

A survey on self-medication for the prevention or treatment of COVID-19 and distrust in healthcare of veterans in a primary care setting in the United States
por: Amenta, Eva, et al.
Publicado: (2022)

The response to the COVID-19 pandemic trusted in pharmacovigilance to diminish communication risk
por: Quintero, Gustavo A.
Publicado: (2022)

Alkalising agents in urinary tract infections: theoretical contraindications, interactions and synergy
por: Kavanagh, Oisín N.
Publicado: (2022)

Risk communication on vaccines during the COVID19 pandemic: is there room for small size or private initiatives? An Israeli experience
por: Fermont, Irene R., et al.
Publicado: (2022)

Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature
por: Eslait-Olaciregui, Sara, et al.
Publicado: (2023)

Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data
por: Steffen, Annika, et al.
Publicado: (2018)

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports
por: Salem, M., et al.
Publicado: (2017)

Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

Pharmacovigilance and assessment of drug safety reports during COVID 19
por: Desai, Mira K
Publicado: (2020)

Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India
por: Thota, Prasad, et al.
Publicado: (2018)

Pharmacovigilance for clinical trials in India: Current practice and areas for reform
por: Brahmachari, Ballari, et al.
Publicado: (2011)

Causality assessment: A brief insight into practices in pharmaceutical industry
por: Naidu, R. Purushotham
Publicado: (2013)

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval
por: Mendell, Jeanne, et al.
Publicado: (2015)

A day in the life of a pharmacovigilance case processor
por: Bhangale, Ritesh, et al.
Publicado: (2017)

Understanding the molecular–pharmaceutical basis of sartan recalls focusing on valsartan
por: Ray, Avik, et al.
Publicado: (2020)

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

A case of intoxication with tea made from Digitalis purpurea
por: Lehmann, Anouk, et al.
Publicado: (2021)

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022)

Global research output in ‘pharmacovigilance’ during 2010–2020
por: Tyagi, Sunil
Publicado: (2022)

Colchicine and macrolides: a cohort study of the risk of adverse outcomes associated with concomitant exposure
por: Tan, Malinda S., et al.
Publicado: (2022)

Vaccines and Bell's palsy: A narrative review
por: Bertin, Blandine, et al.
Publicado: (2023)

The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans
por: Dal-Ré, Rafael
Publicado: (2023)

French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023)

Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)

Pharmacovigilance follow-up of patients in the context of the COVID-19 pandemic
por: Grandvuillemin, Aurélie, et al.
Publicado: (2023)

Role of spontaneous reporting in investigating the relationship between mRNA COVID-19 vaccines and myocarditis: The French perspective
por: Salvo, Francesco, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran)
por: Valnet-Rabier, Marie-Blanche, et al.
Publicado: (2023)

Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series
por: Chamboux, Morgane, et al.
Publicado: (2023)

COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
por: Massy, Nathalie, et al.
Publicado: (2023)

Small intestinal injury in NSAID users suffering from rheumatoid arthritis or osteoarthritis
por: Tachecí, Ilja, et al.
Publicado: (2016)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g9bg6h020mp9kqgfllfrl93a9e